Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AgomAb Therapeutics NVAGMB · Entity 5259 | Director | September 11, 2026 | September 15, 2026 |
| Dianthus Therapeutics, Inc. /DE/DNTH · Entity 1813 | Director · CEO AND PRESIDENT | August 07, 2026 | August 07, 2026 |
| SYNERGY PHARMACEUTICALS, INC.SGYP · Entity 164269 | EVP and Chief Strategy Officer | January 05, 2018 | January 09, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AgomAb Therapeutics NV
Report date September 11, 2026 · Filed September 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.94 · Expires 2036-01-15 | Direct | 57,482 |
Reported balance
After 2026-09-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-11 · Grant · Acquired 57,482 · Balance 57,482 F1: The common shares may be represented by American Depositary Shares, each of which currently represents one common share. F2: The exercise price is reported in U.S. dollars and reflects the conversion from EUR to USD at an exchange rate of $1.1616 per EUR 1.00 as of September 10, 2026. F3: 33% of the shares underlying this option shall vest on September 11, 2027, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The common shares may be represented by American Depositary Shares, each of which currently represents one common share.
F2: The exercise price is reported in U.S. dollars and reflects the conversion from EUR to USD at an exchange rate of $1.1616 per EUR 1.00 as of September 10, 2026.
F3: 33% of the shares underlying this option shall vest on September 11, 2027, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Dianthus Therapeutics, Inc. /DE/
Report date August 07, 2026 · Filed August 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 105,292 |
Reported balance
After 2026-08-07 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2026-08-07 · Exercise / conversion · Acquired 40,000 · Balance 105,292 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2026. |
| Common StockSEC Table I · non-derivative | Direct | 231,292 |
Reported balance
After 2026-08-07 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2026-08-07 · Exercise / conversion · Acquired 126,000 · Balance 231,292 |
| Common StockSEC Table I · non-derivative | Direct | 220,908 |
Reported balance
After 2026-08-07 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2026-08-07 · Sale · Disposed 10,384 · Balance 220,908 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2026. F2: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $106.68 to $107.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. |
| Common StockSEC Table I · non-derivative | Direct | 197,001 |
Reported balance
After 2026-08-07 transaction · row 4
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 4 · 2026-08-07 · Sale · Disposed 23,907 · Balance 197,001 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2026. F3: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.68 to $108.67, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. |
| Common StockSEC Table I · non-derivative | Direct | 194,628 |
Reported balance
After 2026-08-07 transaction · row 5
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 5 · 2026-08-07 · Sale · Disposed 2,373 · Balance 194,628 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2026. F4: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $108.74 to $109.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. |
| Common StockSEC Table I · non-derivative | Direct | 192,092 |
Reported balance
After 2026-08-07 transaction · row 6
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 6 · 2026-08-07 · Sale · Disposed 2,536 · Balance 192,092 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2026. F5: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $109.75 to $110.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. |
| Common StockSEC Table I · non-derivative | Direct | 191,292 |
Reported balance
After 2026-08-07 transaction · row 7
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 7 · 2026-08-07 · Sale · Disposed 800 · Balance 191,292 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2026. |
| Common StockSEC Table I · non-derivative | Direct | 87,102 |
Reported balance
After 2026-08-07 transaction · row 8
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 8 · 2026-08-07 · Sale · Disposed 104,091 · Balance 87,102 F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.52 to $108.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. |
| Common StockSEC Table I · non-derivative | Direct | 65,292 |
Reported balance
After 2026-08-07 transaction · row 9
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 9 · 2026-08-07 · Sale · Disposed 21,909 · Balance 65,292 F7: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $108.57 to $108.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.44 · Expires 2032-06-06 | Direct | 286,004 |
Reported balance
After 2026-08-07 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-08-07 · Exercise / conversion · Disposed 40,000 · Balance 286,004 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2026. F8: The shares of common stock underlying this stock option award vested as to 25% of the shares on November 1, 2022, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.44 · Expires 2032-06-06 | Direct | 160,004 |
Reported balance
After 2026-08-07 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-08-07 · Exercise / conversion · Disposed 126,000 · Balance 160,004 F8: The shares of common stock underlying this stock option award vested as to 25% of the shares on November 1, 2022, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2026.
F2: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $106.68 to $107.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.68 to $108.67, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F4: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $108.74 to $109.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F5: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $109.75 to $110.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.52 to $108.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
F7: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $108.57 to $108.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F8: The shares of common stock underlying this stock option award vested as to 25% of the shares on November 1, 2022, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
SYNERGY PHARMACEUTICALS, INC.
Report date January 05, 2018 · Filed January 09, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $2.18 · Expires 2028-01-05 | Direct | 1,010,000 |
Reported balance
After 2018-01-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-01-05 · Grant · Acquired 280,000 · Balance 1,010,000 F1: 93,333 of the stock options vest on 1/5/2019 and 2020 and 93,334 vest on 1/5/2021. |
Filing footnotes · ownership attribution and instrument terms
F1: 93,333 of the stock options vest on 1/5/2019 and 2020 and 93,334 vest on 1/5/2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 11, 2026 Filed Sep 15, 2026 20:06 UTC | AgomAb Therapeutics NV AGMB · Entity 5259 | GrantStock Option (Right to Buy) · Derivative | 57,482 | $0.00 Strike: $13.94 | $0.00 |
DisclosureSEC source: 0001104659-26-107916 · tm2625420-4_4seq1.xml · derivative · entry 1 Garcia Marino · CIK 0001669866 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,482 Underlying: Common shares · 57,482 shares Expires 2036-01-15 F1 · derivative.exercise_price: The common shares may be represented by American Depositary Shares, each of which currently represents one common share. F2 · derivative.exercise_date: The exercise price is reported in U.S. dollars and reflects the conversion from EUR to USD at an exchange rate of $1.1616 per EUR 1.00 as of September 10, 2026. F3 · derivative.underlying: 33% of the shares underlying this option shall vest on September 11, 2027, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| August 07, 2026 Filed Aug 7, 2026 22:30 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionStock Option (Right to Buy) · Derivative | 126,000 | $0.00 Strike: $8.44 | $0.00 |
DisclosureSEC source: 0001669866-26-000010 · ownership.xml · derivative · entry 11 Garcia Marino · CIK 0001669866 · Director · CEO AND PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 160,004 Underlying: Common Stock · 126,000 shares Expires 2032-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The shares of common stock underlying this stock option award vested as to 25% of the shares on November 1, 2022, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| August 07, 2026 Filed Aug 7, 2026 22:30 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $8.44 | $0.00 |
DisclosureSEC source: 0001669866-26-000010 · ownership.xml · derivative · entry 10 Garcia Marino · CIK 0001669866 · Director · CEO AND PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 286,004 Underlying: Common Stock · 40,000 shares Expires 2032-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2026. F8 · derivative.exercise_date: The shares of common stock underlying this stock option award vested as to 25% of the shares on November 1, 2022, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| August 07, 2026 Filed Aug 7, 2026 22:30 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 21,909 | $108.72 | $2,381,946.48 |
DisclosureSEC source: 0001669866-26-000010 · ownership.xml · nonDerivative · entry 9 Garcia Marino · CIK 0001669866 · Director · CEO AND PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,292 F7 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $108.57 to $108.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 07, 2026 Filed Aug 7, 2026 22:30 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 104,091 | $107.96 | $11,237,664.36 |
DisclosureSEC source: 0001669866-26-000010 · ownership.xml · nonDerivative · entry 8 Garcia Marino · CIK 0001669866 · Director · CEO AND PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,102 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.52 to $108.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| August 07, 2026 Filed Aug 7, 2026 22:30 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 800 | $110.76 | $88,608.00 |
DisclosureSEC source: 0001669866-26-000010 · ownership.xml · nonDerivative · entry 7 Garcia Marino · CIK 0001669866 · Director · CEO AND PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 191,292 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2026. Read SEC document |
| August 07, 2026 Filed Aug 7, 2026 22:30 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 2,536 | $110.02 | $279,010.72 |
DisclosureSEC source: 0001669866-26-000010 · ownership.xml · nonDerivative · entry 6 Garcia Marino · CIK 0001669866 · Director · CEO AND PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 192,092 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2026. F5 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $109.75 to $110.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 07, 2026 Filed Aug 7, 2026 22:30 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 2,373 | $109.10 | $258,894.30 |
DisclosureSEC source: 0001669866-26-000010 · ownership.xml · nonDerivative · entry 5 Garcia Marino · CIK 0001669866 · Director · CEO AND PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 194,628 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2026. F4 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $108.74 to $109.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 07, 2026 Filed Aug 7, 2026 22:30 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 23,907 | $108.05 | $2,583,151.35 |
DisclosureSEC source: 0001669866-26-000010 · ownership.xml · nonDerivative · entry 4 Garcia Marino · CIK 0001669866 · Director · CEO AND PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 197,001 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2026. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.68 to $108.67, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 07, 2026 Filed Aug 7, 2026 22:30 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 10,384 | $107.49 | $1,116,176.16 |
DisclosureSEC source: 0001669866-26-000010 · ownership.xml · nonDerivative · entry 3 Garcia Marino · CIK 0001669866 · Director · CEO AND PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 220,908 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2026. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $106.68 to $107.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 07, 2026 Filed Aug 7, 2026 22:30 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionCommon Stock | 126,000 | $8.44 | $1,063,440.00 |
DisclosureSEC source: 0001669866-26-000010 · ownership.xml · nonDerivative · entry 2 Garcia Marino · CIK 0001669866 · Director · CEO AND PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 231,292 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2026 Filed Aug 7, 2026 22:30 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionCommon Stock | 40,000 | $8.44 | $337,600.00 |
DisclosureSEC source: 0001669866-26-000010 · ownership.xml · nonDerivative · entry 1 Garcia Marino · CIK 0001669866 · Director · CEO AND PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,292 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2026. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 21:22 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,592 | $0.00 Strike: $17.88 | $0.00 |
DisclosureSEC source: 0001669866-26-000007 · ownership.xml · derivative · entry 4 Garcia Marino · CIK 0001669866 · Director · CEO AND PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 269,408 Underlying: Common Stock · 5,592 shares Expires 2034-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 21:22 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionStock Option (Right to Buy) · Derivative | 59,700 | $0.00 Strike: $6.70 | $0.00 |
DisclosureSEC source: 0001669866-26-000007 · ownership.xml · derivative · entry 3 Garcia Marino · CIK 0001669866 · Director · CEO AND PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41 Underlying: Common Stock · 59,700 shares Expires 2031-11-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vested as to 25% of the shares on November 1, 2022, with the remaining three quarters vested in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 21:22 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionCommon Stock | 5,592 | $17.88 | $99,984.96 |
DisclosureSEC source: 0001669866-26-000007 · ownership.xml · nonDerivative · entry 2 Garcia Marino · CIK 0001669866 · Director · CEO AND PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,292 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 21:22 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionCommon Stock | 59,700 | $6.70 | $399,990.00 |
DisclosureSEC source: 0001669866-26-000007 · ownership.xml · nonDerivative · entry 1 Garcia Marino · CIK 0001669866 · Director · CEO AND PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2026 Filed Mar 14, 2026 00:30 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionStock Option (Right to Buy) · Derivative | 122,918 | $0.00 Strike: $6.70 | $0.00 |
DisclosureSEC source: 0001669866-26-000005 · ownership.xml · derivative · entry 7 Garcia Marino · CIK 0001669866 · Director · CEO AND PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,741 Underlying: Common Stock · 122,918 shares Expires 2031-11-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2025. F5 · derivative.exercise_date: The shares of common stock underlying this stock option award vested as to 25% of the shares on November 1, 2022, with the remaining three quarters vested in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| March 12, 2026 Filed Mar 14, 2026 00:30 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 900 | $85.53 | $76,977.00 |
DisclosureSEC source: 0001669866-26-000005 · ownership.xml · nonDerivative · entry 6 Garcia Marino · CIK 0001669866 · Director · CEO AND PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2025. Read SEC document |
| March 12, 2026 Filed Mar 14, 2026 00:30 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 200 | $83.38 | $16,676.00 |
DisclosureSEC source: 0001669866-26-000005 · ownership.xml · nonDerivative · entry 5 Garcia Marino · CIK 0001669866 · Director · CEO AND PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 900 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2025. Read SEC document |
| March 12, 2026 Filed Mar 14, 2026 00:30 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 12,796 | $82.60 | $1,056,949.60 |
DisclosureSEC source: 0001669866-26-000005 · ownership.xml · nonDerivative · entry 4 Garcia Marino · CIK 0001669866 · Director · CEO AND PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,100 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2025. F4 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $82.29 to $83.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 12, 2026 Filed Mar 14, 2026 00:30 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 65,517 | $81.74 | $5,355,359.58 |
DisclosureSEC source: 0001669866-26-000005 · ownership.xml · nonDerivative · entry 3 Garcia Marino · CIK 0001669866 · Director · CEO AND PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,896 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2025. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $81.29 to $82.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 12, 2026 Filed Mar 14, 2026 00:30 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 43,505 | $80.69 | $3,510,418.45 |
DisclosureSEC source: 0001669866-26-000005 · ownership.xml · nonDerivative · entry 2 Garcia Marino · CIK 0001669866 · Director · CEO AND PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,413 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2025. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $80.29 to $81.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 12, 2026 Filed Mar 14, 2026 00:30 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionCommon Stock | 122,918 | $6.70 | $823,550.60 |
DisclosureSEC source: 0001669866-26-000005 · ownership.xml · nonDerivative · entry 1 Garcia Marino · CIK 0001669866 · Director · CEO AND PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 122,918 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2025. Read SEC document |
| February 03, 2026 Filed Feb 4, 2026 22:39 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 355,000 | $0.00 Strike: $52.46 | $0.00 |
DisclosureSEC source: 0001669866-26-000002 · ownership.xml · derivative · entry 1 Garcia Marino · CIK 0001669866 · Director · CEO AND PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 355,000 Underlying: Common Stock · 355,000 shares Expires 2036-02-03 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award will vest in equal monthly installments over the four years after January 1, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| September 30, 2025 Filed Oct 3, 2025 23:00 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $39.35 | $0.00 |
DisclosureSEC source: 0001669866-25-000004 · ownership.xml · derivative · entry 1 Garcia Marino · CIK 0001669866 · Director · CEO AND PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2035-09-30 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award will vest in equal monthly installments over the four years after September 30, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 21:13 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 340,000 | $0.00 Strike: $22.07 | $0.00 |
DisclosureSEC source: 0000950170-25-013443 · ownership.xml · derivative · entry 1 Garcia Marino · CIK 0001669866 · Director · CEO AND PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 340,000 Underlying: Common Stock · 340,000 shares Expires 2035-02-02 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award will vest in equal monthly installments over the four years after January 1, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| May 23, 2024 Filed May 29, 2024 00:03 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 243,000 | $0.00 Strike: $21.77 | $0.00 |
DisclosureSEC source: 0000950170-24-065562 · ownership.xml · derivative · entry 1 Garcia Marino · CIK 0001669866 · Director · CEO AND PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 243,000 Underlying: Common Stock · 243,000 shares Expires 2034-05-22 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award will vest in equal monthly installments over the four years after May 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| January 24, 2024 Filed Jan 26, 2024 21:36 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 275,000 | $0.00 Strike: $17.88 | $0.00 |
DisclosureSEC source: 0000950170-24-007979 · ownership.xml · derivative · entry 1 Garcia Marino · CIK 0001669866 · Director · CEO AND PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2034-01-23 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award will vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| January 05, 2018 Filed Jan 9, 2018 22:01 UTC | SYNERGY PHARMACEUTICALS, INC. SGYP · Entity 164269 | GrantStock Options · Derivative | 280,000 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001104659-18-001492 · a4.xml · derivative · entry 1 Garcia Marino · CIK 0001669866 · EVP and Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,010,000 Underlying: Common Stock · 280,000 shares Expires 2028-01-05 F1 · derivative.exercise_date: 93,333 of the stock options vest on 1/5/2019 and 2020 and 93,334 vest on 1/5/2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.